Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | TDP2 | O95551 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | CASP9 | P55211 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29824315 | 0.98 | CA12 (0.42) | CA12CA9MAOACES1TDP2 | |
| SCHEMBL57213 | 0.98 | CA12 (0.42) | CA12CA9MAOACES1TDP2 | |
| Hydrochloric Acid SCHEMBL2455497 | 0.96 | CA12 (0.41) | CA12CA9MAOACES1TDP2 | |
| Hydrochloric Acid SCHEMBL7005883 | 0.96 | CA12 (0.41) | CA12CA9MAOACES1TDP2 | |
| Acetamide SCHEMBL1668160 | 0.86 | ALDH1A1 (0.38) | CA12CA9MAOACES1KMT2A | |
| SCHEMBL207528 | 0.78 | CES1 (0.48) | CA12CA9MAOACES1TDP2 | |
| SCHEMBL4771824 | 0.72 | MAOA (0.34) | MAOACES1MAOBBCHETSHR | |
| SCHEMBL7614336 | 0.72 | MAOA (0.33) | CA12CA9MAOACES1MAOB | |
| SCHEMBL7825908 | 0.72 | MAOA (0.38) | CA12CA9MAOACES1TDP2 | |
| SCHEMBL1550523 | 0.71 | MAOA (0.44) | CA9MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640241-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-09-28 | — | — | EP | disclosed |
| EP-1667978-B1 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8338449-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100256698-A1 | Isoquinolinone Potassium Channel Inhibitors | MERCK & CO., INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7781457-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7741322-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7723352-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME (US) | 2010-05-25 | — | — | US | disclosed |
| US-7709476-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1896416-B1 | SUBSTITUTED HETEROCYCLES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS (FR) | 2008-10-15 | — | — | EP | disclosed |
| US-20080227778-A1 | Isoquinolinone Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2008-09-18 | — | — | US | disclosed |
| US-20060270704-A1 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2006-11-30 | — | — | US | disclosed |
| CN-1856473-A | Isoquinolinone potassium channel inhibitors | MERCK & CO INC (US) | 2006-11-01 | — | — | CN | disclosed |
| CN-1856476-A | Isoquinolinone potassium channel inhibitors | MERCK & CO INC (US) | 2006-11-01 | — | — | CN | disclosed |
| CN-1856476-A | Isoquinolinone potassium channel inhibitors | MERCK & CO INC (US) | 2006-11-01 | — | — | CN | disclosed |
| CN-1856473-A | Isoquinolinone potassium channel inhibitors | MERCK & CO INC (US) | 2006-11-01 | — | — | CN | disclosed |
| CN-1856474-A | Isoquinolinone potassium channel inhibitors | MERCK & CO INC (US) | 2006-11-01 | — | — | CN | disclosed |
| CN-1856472-A | Isoquinolinone potassium channel inhibitors | MERCK & CO INC (US) | 2006-11-01 | — | — | CN | disclosed |
| CN-1856472-A | Isoquinolinone potassium channel inhibitors | MERCK & CO INC (US) | 2006-11-01 | — | — | CN | disclosed |
| US-6870055-B2 | Isoquinolinone potassium channels inhibitors | MERCK & CO., INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040044030-A1 | Isoquinolinone potassium channels inhibitors | MERCK SHARP & DOHME CORP. | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227778-A1 | Isoquinolinone Potassium Channel Inhibitors | KCNJ2, KCNQ1, KCNQ2 | CA12 4718/4885CA9 4363/4885MAOA 3281/4885 |
| US-20040044030-A1 | Isoquinolinone potassium channels inhibitors | KCNQ5, KCNQ1, KCNQ2 | CA12 4340/4885CA9 2260/4885MAOA 3661/4885 |
| US-20060270704-A1 | Isoquinolinone potassium channel inhibitors | KCNJ2, KCNQ1, KCNQ2 | CA12 4652/4885CA9 4016/4885MAOA 3016/4885 |
| US-20100256698-A1 | Isoquinolinone Potassium Channel Inhibitors | KCNJ2, KCNQ1, KCNQ2 | CA12 4689/4885CA9 4336/4885MAOA 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.